Related Articles
Molecular and cellular mechanisms of castration resistant prostate cancer (Review)
A randomized phase III trial of personalized peptide vaccination for castration‑resistant prostate cancer progressing after docetaxel
Identification of favorable subgroups for alternative anti‑androgen therapy in castration‑resistant prostate cancer
Partial response of liver metastases treated with abiraterone in castration-resistant prostate cancer: A case report
Calpain and AR-V7: Two potential therapeutic targets to overcome acquired docetaxel resistance in castration-resistant prostate cancer cells